Максим Владимирович Артемов
Максим Владимирович Артемов has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- A. L. Dolbov
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
2 shared publications - A. A. Tretyakov
Russian Scientific Center of Radiology and Surgical Technologies named after Academician A. M. Granov
1 shared publication - Aleksei Yu. Kneev
Federal State Budgetary Institution «Russian Scientific Center of Radiology and Surgical Technologies named after Academician A. M. Granov» of the Ministry of Health of the Russian Federation (FSBI «RSCRT named after Academician A. M. Granov» of the Ministry of Health of Russia), Saint-Petersburg, Russia
1 shared publication - Artem V. Kartashev
A.M. Granov Russian Research Center of Radiology and Surgical Technologies
1 shared publication - D. A. Vazhenina
A. Granov Russian Scientific Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation
1 shared publication - Daria V. Ryzhkova
Federal State Budgetary Institution “Almazov National Medical Research Centre” of the Ministry of Health of the Russian Federation
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (3) , 49-59
Diagnostic Significance of MRI in the Assessment of Meningiomas after Stereotactic Radiosurgery: Morphological Features and Dynamics of Changes
Purpose : To improve the efficiency of diagnostic monitoring of patients with meningiomas after stereotactic radiosurgery. Materials and methods : This retrospective, single-center study included 50 patients with meningiomas who underwent stereotactic radiosurgery (SRS) using the Gamma Knife ICON (Elekta). The mean age was 64.9 ± 11.6 years. Skull base meningiomas were detected in 21 of 50 patients (42.0 %), parasagittal meningiomas in 18 of 50 (36.0 %), and convexital meningiomas in 11 of 50 (22.0 %). Histological verification (based on the results of the previous resection) was performed in 24 patients: Grade I — 10, Grade II — 8, Grade III — 6. Follow-up MRI examinations were performed 3, 6, and 12–14 months after SRS. For each tumor, changes in area (using the RANO criteria) and volume were determined; agreement between the methods was assessed using the Cohen’s kappa coefficient. In addition, qualitative MRI features were assessed: contrast enhancement pattern, perifocal edema, margin clarity, and the presence of new lesions. Results : According to the volume classification, progression was observed in 12 of 50 patients (24.0 %; 95 % CI: 14.3–37.4), stabilization in 32 of 50 (64.0 %), and response in 6 of 50 (12.0 %). According to the RANO criteria: 10 of 50 (20.0 %) / 21 of 50 (42.0 %) / 19 of 50 (38.0 %), respectively. The agreement between the two methods was 68.0 % (Cohen’s kappa 0.498). The grade of malignancy was significantly associated with progression (chi-square p = 0.043; pairwise Grade I vs III: p = 0.035); localization was not (p = 0.84). A combination of qualitative MR features demonstrated high diagnostic efficacy: persistent heterogeneous contrast enhancement at 12-14 months, combined with pathological dynamics of perifocal changes. Each feature was characterized by a different sensitivityspecificity ratio: the appearance of new lesions — Sn 41.7 %, Sp 100 %; perifocal edema — Sn 41.7 %, Sp 92.1 %; the appearance of fuzzy margins — Sn 25.0 %, Sp 100 %. Conclusion : Quantitative volumetric assessment of meningiomas after SRS proved more sensitive compared to area-based assessment (RANO), additionally identifying cases of occult progression in 2 patients (4 %). The grade of meningioma malignancy is a significant factor associated with the risk of progression; a significant difference was found between Grade I and Grade III. The location of the lesion did not affect treatment outcomes. A set of qualitative MRI features (characteristics and dynamics of contrast enhancement, perifocal edema, clarity of contours, new lesions) provides the basis for differential diagnosis of true progression and post-radiation reactions.
- 5 October 2026
- Published by Non-profit partnership Society of Interventional Oncoradiologists in Journal of oncology: diagnostic radiology and radiotherapy
- Vol. 9 (3) , 49-59
Open AccessDiagnostic Significance of MRI in the Assessment of Meningiomas after Stereotactic Radiosurgery: Morphological Features and Dynamics of Changes
Purpose : To improve the efficiency of diagnostic monitoring of patients with meningiomas after stereotactic radiosurgery. Materials and methods : This retrospective, single-center study included 50 patients with meningiomas who underwent stereotactic radiosurgery (SRS) using the Gamma Knife ICON (Elekta). The mean age was 64.9 ± 11.6 years. Skull base meningiomas were detected in 21 of 50 patients (42.0 %), parasagittal meningiomas in 18 of 50 (36.0 %), and convexital meningiomas in 11 of 50 (22.0 %). Histological verification (based on the results of the previous resection) was performed in 24 patients: Grade I — 10, Grade II — 8, Grade III — 6. Follow-up MRI examinations were performed 3, 6, and 12–14 months after SRS. For each tumor, changes in area (using the RANO criteria) and volume were determined; agreement between the methods was assessed using the Cohen’s kappa coefficient. In addition, qualitative MRI features were assessed: contrast enhancement pattern, perifocal edema, margin clarity, and the presence of new lesions. Results : According to the volume classification, progression was observed in 12 of 50 patients (24.0 %; 95 % CI: 14.3–37.4), stabilization in 32 of 50 (64.0 %), and response in 6 of 50 (12.0 %). According to the RANO criteria: 10 of 50 (20.0 %) / 21 of 50 (42.0 %) / 19 of 50 (38.0 %), respectively. The agreement between the two methods was 68.0 % (Cohen’s kappa 0.498). The grade of malignancy was significantly associated with progression (chi-square p = 0.043; pairwise Grade I vs III: p = 0.035); localization was not (p = 0.84). A combination of qualitative MR features demonstrated high diagnostic efficacy: persistent heterogeneous contrast enhancement at 12-14 months, combined with pathological dynamics of perifocal changes. Each feature was characterized by a different sensitivityspecificity ratio: the appearance of new lesions — Sn 41.7 %, Sp 100 %; perifocal edema — Sn 41.7 %, Sp 92.1 %; the appearance of fuzzy margins — Sn 25.0 %, Sp 100 %. Conclusion : Quantitative volumetric assessment of meningiomas after SRS proved more sensitive compared to area-based assessment (RANO), additionally identifying cases of occult progression in 2 patients (4 %). The grade of meningioma malignancy is a significant factor associated with the risk of progression; a significant difference was found between Grade I and Grade III. The location of the lesion did not affect treatment outcomes. A set of qualitative MRI features (characteristics and dynamics of contrast enhancement, perifocal edema, clarity of contours, new lesions) provides the basis for differential diagnosis of true progression and post-radiation reactions.
- 1 January 2026
- Published by BIBLIO-GLOBUS Publishing House in Russian Journal of Innovation Economics
- Vol. 16 (3) , 1335-1360
«Институт корпоративной зрелости» как созидательная основа становления лучшей практики построения бизнеса в формате контракта жизненного цикла высокотехнологичной продукции
Обоснована актуальность системного становления «Института корпоративной зрелости» при построении бизнеса в формате контракта жизненного цикла высокотехнологичной продукции под воздействием глобальных вызовов и трендов наблюдаемого вхождения экономики в эпоху сингулярности и турбулентности на стыке Четвертой и Пятой промышленных революций. Определено понятие «Института корпоративной зрелости» как неосязаемого актива компании, осуществляющего синергию стратегической постановки и оперативного решения приоритетных задач, обеспечивающую ее устойчивое развитие, что представляется непреложным при смене управленческих парадигм. Раскрыто предметное содержание феномена «Институт корпоративной зрелости» в контексте тринитарно-коннективного определения системно-структурной целостности таких концептуальных основ, как: «Институт межкорпоративного разумного доверия», «Институт межкорпоративной солидарной экономики» и «Институт командного лидерства». Раскрыто обретение эффективности «Института корпоративной зрелости» в контексте наличия надлежащей синергии стратегического и оперативного управления на основе тесно сочлененной корпоративной деятельности исполнительного топ-менеджмента и Советов директоров компаний – участниками построения бизнеса в формате КЖЦ ВТП.
- 1 January 2026
- Published by BIBLIO-GLOBUS Publishing House in Russian Journal of Innovation Economics
- Vol. 16 (3) , 1335-1360
«Институт корпоративной зрелости» как созидательная основа становления лучшей практики построения бизнеса в формате контракта жизненного цикла высокотехнологичной продукции
Обоснована актуальность системного становления «Института корпоративной зрелости» при построении бизнеса в формате контракта жизненного цикла высокотехнологичной продукции под воздействием глобальных вызовов и трендов наблюдаемого вхождения экономики в эпоху сингулярности и турбулентности на стыке Четвертой и Пятой промышленных революций. Определено понятие «Института корпоративной зрелости» как неосязаемого актива компании, осуществляющего синергию стратегической постановки и оперативного решения приоритетных задач, обеспечивающую ее устойчивое развитие, что представляется непреложным при смене управленческих парадигм. Раскрыто предметное содержание феномена «Институт корпоративной зрелости» в контексте тринитарно-коннективного определения системно-структурной целостности таких концептуальных основ, как: «Институт межкорпоративного разумного доверия», «Институт межкорпоративной солидарной экономики» и «Институт командного лидерства». Раскрыто обретение эффективности «Института корпоративной зрелости» в контексте наличия надлежащей синергии стратегического и оперативного управления на основе тесно сочлененной корпоративной деятельности исполнительного топ-менеджмента и Советов директоров компаний – участниками построения бизнеса в формате КЖЦ ВТП.
- Open Access
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Comparative Performance of 68Ga-FAPI-04 and ¹8F-FDG PET/CT for Detection of Malignant Tumors and Metastases
Введение. Данные о диагностическом преимуществе радиофармацевтического лекарственного препарата (РФЛП) на основе ингибитора белка активации фибробластов (68Ga-ФАПИ-04) над хорошо себя зарекомендовавшим в онкологии туморотропным РФЛП 18F-ФДГ (18F-фтордезоксиглюкозой) изучены недостаточно на небольших когортах пациентов, а доступные литературные сведения противоречивы. Цель. — Выполнить сравнительный анализ информативности позитронно-эмиссионной томографии, совмещенной с рентгеновской компьютерной томографией (ПЭТ/КТ), с 68Ga-ФАПИ-04 и 18F-ФДГ в идентификации злокачественных опухолей и их метастазов. Материалы и методы. В исследование включено 66 пациентов: 30 мужчин и 36 женщин, медиана возраста — 54 года (22-83 года), с гистологически верифицированными злокачественными новообразованиями (ЗНО) различных локализаций. ПЭТ/КТ с двумя РФЛП — 68Ga-ФАПИ-04 и 18F-ФДГ, выполнена до начала противоопухолевого лечения 34 (52 %) из 66 пациентов с целью стадирования опухолевого процесса, 32 (48 %) пациентам ПЭТ/КТ проводили с целью диагностики местного рецидива опухоли и метастазов. Интервал между исследованиями не превышал семь дней. Результаты. Чувствительность 68Ga-ФАПИ-04 в выявлении как первичной опухоли, так и оценки распространенности заболевания была достоверно выше чувствительности 18F-ФДГ и составила 93,9 против 77,3 %, p = 0,006. У 33 (97,1 %) из 34 пациентов с первичными новообразованиями была выявлена патологическая гиперфиксация 68Ga-ФАПИ-04 в опухоли, при ПЭТ/КТ с 18F-ФДГ факт наличия первичной опухоли был установлен только в 24 случаях (70,6 %). Общий объем гиперэкспрессии белка активации фибробластов (fibroblast activation protein, FAP) был достоверно выше при исследовании с 68Ga-ФАПИ-04, чем общий метаболический объем опухоли (total metabolic tumor volume, TMTV) при ПЭТ/КТ с 18F-ФДГ: 34,7 (11;75,66) против 11,07 (0; 49,5) (p = 0,021). Чувствительность в выявлении костных метастазов и метастазов в печень была выше при исследовании с 68Ga-ФАПИ-04 по сравнению c 18F-ФДГ (92,6 против 85,2 %, p = 0,046; и 90,2 против 68,3 % соответственно, p = 0,014). Чувствительность ПЭТ/КТ в выявлении метастазов в лимфатические узлы была выше для 68Ga-ФАПИ-04 (81,1 против 73 % соответственно, p = 0,044), но зависела от размеров лимфатических узлов. Выводы. ПЭТ/КТ с 68Ga-ФАПИ-04 превосходит по чувствительности ПЭТ/КТ 18F-ФДГ в идентификации первичной и рецидивной опухоли, а также метастатической диссеминации и опухолевой нагрузки.
- 5 November 2025
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 71 (5)
Open AccessComparative Performance of 68Ga-FAPI-04 and ¹8F-FDG PET/CT for Detection of Malignant Tumors and Metastases
Введение. Данные о диагностическом преимуществе радиофармацевтического лекарственного препарата (РФЛП) на основе ингибитора белка активации фибробластов (68Ga-ФАПИ-04) над хорошо себя зарекомендовавшим в онкологии туморотропным РФЛП 18F-ФДГ (18F-фтордезоксиглюкозой) изучены недостаточно на небольших когортах пациентов, а доступные литературные сведения противоречивы. Цель. — Выполнить сравнительный анализ информативности позитронно-эмиссионной томографии, совмещенной с рентгеновской компьютерной томографией (ПЭТ/КТ), с 68Ga-ФАПИ-04 и 18F-ФДГ в идентификации злокачественных опухолей и их метастазов. Материалы и методы. В исследование включено 66 пациентов: 30 мужчин и 36 женщин, медиана возраста — 54 года (22-83 года), с гистологически верифицированными злокачественными новообразованиями (ЗНО) различных локализаций. ПЭТ/КТ с двумя РФЛП — 68Ga-ФАПИ-04 и 18F-ФДГ, выполнена до начала противоопухолевого лечения 34 (52 %) из 66 пациентов с целью стадирования опухолевого процесса, 32 (48 %) пациентам ПЭТ/КТ проводили с целью диагностики местного рецидива опухоли и метастазов. Интервал между исследованиями не превышал семь дней. Результаты. Чувствительность 68Ga-ФАПИ-04 в выявлении как первичной опухоли, так и оценки распространенности заболевания была достоверно выше чувствительности 18F-ФДГ и составила 93,9 против 77,3 %, p = 0,006. У 33 (97,1 %) из 34 пациентов с первичными новообразованиями была выявлена патологическая гиперфиксация 68Ga-ФАПИ-04 в опухоли, при ПЭТ/КТ с 18F-ФДГ факт наличия первичной опухоли был установлен только в 24 случаях (70,6 %). Общий объем гиперэкспрессии белка активации фибробластов (fibroblast activation protein, FAP) был достоверно выше при исследовании с 68Ga-ФАПИ-04, чем общий метаболический объем опухоли (total metabolic tumor volume, TMTV) при ПЭТ/КТ с 18F-ФДГ: 34,7 (11;75,66) против 11,07 (0; 49,5) (p = 0,021). Чувствительность в выявлении костных метастазов и метастазов в печень была выше при исследовании с 68Ga-ФАПИ-04 по сравнению c 18F-ФДГ (92,6 против 85,2 %, p = 0,046; и 90,2 против 68,3 % соответственно, p = 0,014). Чувствительность ПЭТ/КТ в выявлении метастазов в лимфатические узлы была выше для 68Ga-ФАПИ-04 (81,1 против 73 % соответственно, p = 0,044), но зависела от размеров лимфатических узлов. Выводы. ПЭТ/КТ с 68Ga-ФАПИ-04 превосходит по чувствительности ПЭТ/КТ 18F-ФДГ в идентификации первичной и рецидивной опухоли, а также метастатической диссеминации и опухолевой нагрузки.
- Open Access
- 24 July 2025
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 16 (2) , 74-83
Magnetic resonance imaging in the detection of local prostate cancer recurrence in patients with various PSA levels: a retrospective study
INTRODUCTION: Prostate cancer (PCa) is one of the most common cancer diseases. Approximately 30% of patients undergoing radical prostatectomy develop biochemical recurrence within the first 2 years after completion of treatment. One of the leading and available methods for diagnosing local recurrence of prostate cancer is multiparametric magnetic resonance imaging (mpMRI).OBJECTIVE: To determine the effectiveness of mpMRI in detecting local recurrence of PCa in patients after radical prostatectomy (RP) with different levels of total prostate-specific antigen (tPSA).MATERIALS AND METHODS: mpMRI of the pelvis was performed in 118 patients with biochemical relapse of PCa. The criteria for inclusion of patients in the retrospective study were the absence of previous radiation and hormonal therapy. Patients with positive surgical margins were excluded from the study. 46 patients were at low risk of PCa progression, 38 patients were at intermediate risk, and 34 patients were at high risk. Median obPSA 1.72 ng/ml (range 0.22 to 22.19 ng/ml). Median biochemical relapse 11 months. Patients were divided into groups depending on the level of obPSA (I group 0.2–0.5 ng/ml; II group 0.5–1.0 ng/ml; III group 1.0–3.0 ng/ml; IV group more than 3.0 ng/ml). Interpretation of the results was carried out according to the unified reporting system for assessing local recurrence of prostate cancer in patients after RP and RT — prostate imaging recurrence reporting (PI-RR). The probability of local recurrence of prostate cancer depending on the level of obPSA was analyzed using a statistical logistic regression model.DISCUSSION: Early diagnosis of PCa recurrence includes the need to identify local or distant recurrence, determine its volume and precise localization. mpMRI is highly effective in patients with BCR after RP with a total PSA level of more than 1 ng/ml. With a lower PSA level, the percentage of local recurrence detection is lower, which may be due to the small size of the recurrent lesion. In patients with biochemical recurrence of PCa, when mpMRI data indicate a low or uncertain probability of recurrence (PI-RR 1, 2 and 3), PET/CT with 68Ga-PSMA is recommended to exclude distant and regional metastases, as well as as an additional diagnostic method for detecting local recurrence of PCa.CONCLUSION: mpMRI is a highly effective diagnostic method for biochemical recurrence of prostate cancer, which allows for a personalized approach to further treatment. A significant relationship was found between the level of total PSA and the probability of detecting local recurrence according to mpMRI data. Local recurrence of prostate cancer is most often detected at a PSA level above 1 ng/ml, with a sensitivity of 91.8% and a specificity of 88.9%. With a lower value of total PSA, sensitivity and specificity decrease. With a recurrence focus value of ≥7.8 mm, local recurrence is confirmed in 90.4% of patients with subsequent histological examination.
- 24 July 2025
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 16 (2) , 74-83
Open AccessMagnetic resonance imaging in the detection of local prostate cancer recurrence in patients with various PSA levels: a retrospective study
INTRODUCTION: Prostate cancer (PCa) is one of the most common cancer diseases. Approximately 30% of patients undergoing radical prostatectomy develop biochemical recurrence within the first 2 years after completion of treatment. One of the leading and available methods for diagnosing local recurrence of prostate cancer is multiparametric magnetic resonance imaging (mpMRI).OBJECTIVE: To determine the effectiveness of mpMRI in detecting local recurrence of PCa in patients after radical prostatectomy (RP) with different levels of total prostate-specific antigen (tPSA).MATERIALS AND METHODS: mpMRI of the pelvis was performed in 118 patients with biochemical relapse of PCa. The criteria for inclusion of patients in the retrospective study were the absence of previous radiation and hormonal therapy. Patients with positive surgical margins were excluded from the study. 46 patients were at low risk of PCa progression, 38 patients were at intermediate risk, and 34 patients were at high risk. Median obPSA 1.72 ng/ml (range 0.22 to 22.19 ng/ml). Median biochemical relapse 11 months. Patients were divided into groups depending on the level of obPSA (I group 0.2–0.5 ng/ml; II group 0.5–1.0 ng/ml; III group 1.0–3.0 ng/ml; IV group more than 3.0 ng/ml). Interpretation of the results was carried out according to the unified reporting system for assessing local recurrence of prostate cancer in patients after RP and RT — prostate imaging recurrence reporting (PI-RR). The probability of local recurrence of prostate cancer depending on the level of obPSA was analyzed using a statistical logistic regression model.DISCUSSION: Early diagnosis of PCa recurrence includes the need to identify local or distant recurrence, determine its volume and precise localization. mpMRI is highly effective in patients with BCR after RP with a total PSA level of more than 1 ng/ml. With a lower PSA level, the percentage of local recurrence detection is lower, which may be due to the small size of the recurrent lesion. In patients with biochemical recurrence of PCa, when mpMRI data indicate a low or uncertain probability of recurrence (PI-RR 1, 2 and 3), PET/CT with 68Ga-PSMA is recommended to exclude distant and regional metastases, as well as as an additional diagnostic method for detecting local recurrence of PCa.CONCLUSION: mpMRI is a highly effective diagnostic method for biochemical recurrence of prostate cancer, which allows for a personalized approach to further treatment. A significant relationship was found between the level of total PSA and the probability of detecting local recurrence according to mpMRI data. Local recurrence of prostate cancer is most often detected at a PSA level above 1 ng/ml, with a sensitivity of 91.8% and a specificity of 88.9%. With a lower value of total PSA, sensitivity and specificity decrease. With a recurrence focus value of ≥7.8 mm, local recurrence is confirmed in 90.4% of patients with subsequent histological examination.
- Open Access
- 9 August 2024
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 15 (2) , 118-121
Leiomyoma of bladder: a clinical case
Bladder leiomyoma is a rare benign bladder tumor. Our clinical observation presents a bladder leiomyoma with symptoms of urinary tract obstruction of a 40-year-old woman who came to the outpatient department with complaints of blood in the urine, discomfort in the area of the bosom articulation, and general malaise. She was examined by a urologist and referred for additional examination (ultrasound, MRI with intravenous contrasting). According to magnetic resonance characteristics, this pathologic formation has hypointense signal on T1 and T2 IP, with signal restriction at DWI, with active accumulation of contrast agent. Transurethral resection of bladder tumor is the main method of treatment of small endovesical tumors.
- 9 August 2024
- Published by Baltic Medical Education Center in Diagnostic radiology and radiotherapy
- Vol. 15 (2) , 118-121
Open AccessLeiomyoma of bladder: a clinical case
Bladder leiomyoma is a rare benign bladder tumor. Our clinical observation presents a bladder leiomyoma with symptoms of urinary tract obstruction of a 40-year-old woman who came to the outpatient department with complaints of blood in the urine, discomfort in the area of the bosom articulation, and general malaise. She was examined by a urologist and referred for additional examination (ultrasound, MRI with intravenous contrasting). According to magnetic resonance characteristics, this pathologic formation has hypointense signal on T1 and T2 IP, with signal restriction at DWI, with active accumulation of contrast agent. Transurethral resection of bladder tumor is the main method of treatment of small endovesical tumors.
- Open Access
- 23 May 2024
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 41 (2) , 130-135
Migration of Hem-o-Lok clips into the bladder after radical prostatectomy – own experience
Non-absorbable polymer Hem-o-Lok clips are widely used during nerve-sparing radical prostatectomy for clipping of the neurovascular bundle, as well as for rapid knotless fixation of sutures during the formation of urethrovesical anastomosis. At the same time, cases of migration of Hem-o-Lok clips into the bladder at various times after RP have been described. Our retrospective analysis of 1321 patients, who underwent laparoscopic radical prostatectomy at A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies from 2014 to 2023, revealed 3 cases of Hem-o-Lok clip intravesical migration. Also, to search for similar cases of this rare complication a literature review was conducted. The frequency of postoperative intra-bladder clip migration in our study was 0.23 % (3/1321). One case of spontaneous clip passage was observed 3 months later the radical prostatectomy. In two other cases, long-term symptoms of dysuria (in 7 months and 4 years, respectively) revealed clip incrustation, which led to the removal of the clips through endoscopic intervention and laser cystolithotripsy. Despite the low incidence of this complication, the use of Hem-o-Lok clips during laparoscopic radical prostatectomy, should be minimized reasonably, particularly during the urethro-vesical anastomosis formation. If lower urinary tract symptoms and/or hematuria occur at any point in the postoperative period, it’s advisable to conduct an instrumental examination of the bladder to rule out potential clip migration and possible incrustation.
- 23 May 2024
- Published by ECO-Vector LLC in Perm Medical Journal
- Vol. 41 (2) , 130-135
Open AccessMigration of Hem-o-Lok clips into the bladder after radical prostatectomy – own experience
Non-absorbable polymer Hem-o-Lok clips are widely used during nerve-sparing radical prostatectomy for clipping of the neurovascular bundle, as well as for rapid knotless fixation of sutures during the formation of urethrovesical anastomosis. At the same time, cases of migration of Hem-o-Lok clips into the bladder at various times after RP have been described. Our retrospective analysis of 1321 patients, who underwent laparoscopic radical prostatectomy at A.M. Granov Russian Scientific Center of Radiology and Surgical Technologies from 2014 to 2023, revealed 3 cases of Hem-o-Lok clip intravesical migration. Also, to search for similar cases of this rare complication a literature review was conducted. The frequency of postoperative intra-bladder clip migration in our study was 0.23 % (3/1321). One case of spontaneous clip passage was observed 3 months later the radical prostatectomy. In two other cases, long-term symptoms of dysuria (in 7 months and 4 years, respectively) revealed clip incrustation, which led to the removal of the clips through endoscopic intervention and laser cystolithotripsy. Despite the low incidence of this complication, the use of Hem-o-Lok clips during laparoscopic radical prostatectomy, should be minimized reasonably, particularly during the urethro-vesical anastomosis formation. If lower urinary tract symptoms and/or hematuria occur at any point in the postoperative period, it’s advisable to conduct an instrumental examination of the bladder to rule out potential clip migration and possible incrustation.